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Objectives (1) To identify pregnancies associated with use of the contraceptive implants Implanon 
and Nexplanon in the UK during two five-year reporting periods. (2) To classify the possible reasons 
for device failure in cases reported for each implant. (3) To examine any differences between 
reasons for pregnancies associated with these products. 
Study design Extraction of data from the UK spontaneous reporting system for adverse drug 
reactions in relation to etonogestrel implants.  Reports indicating pregnancy were identified for the 
periods 2005-2009 (Implanon) and 2012-2016 (Nexplanon). Possible reasons for failure of the 
method in each reported case were assigned to one of eight pre-determined categories. 
Results After exclusions, 229 Implanon cases and 234 Nexplanon cases contained sufficient 
information for analysis. True method failures accounted for a majority of the pregnancies in those 
using contraceptive implants (58%); the next most common cause was missing implants (26% of 
pregnancies). In all categories of case there was no difference in frequency of pregnancy when the 
two time periods were compared. 
Conclusions There is still potential for greater avoidance of pregnancies associated with etonogestrel 
implant use. 
Implications This study underscores the continuing need for taking a full drug history, timing the 
insertion on days 1 – 5 or according to recommended quick starting routines and palpating the arm 








• Although etonogestrel implants are a highly effective form of long-acting reversible 
contraception, unintended pregnancies continue to be reported in post-marketing use.  
• The main reasons for contraceptive failure of etonogestrel devices in ‘real life’ use include 
true method failure, missing implants (most likely due to non-insertions) and drug 
interactions. 
• The proportion of failures for each device were not significantly different for Nexplanon 








Etonogestrel implants (Implanon and Nexplanon or Implanon NXT) are highly effective methods of 
contraception with a licensed lifespan of three years. Combined data from 13 clinical trials of 
Implanon showed no pregnancies during 4,103 woman-years of exposure; the Pearl Index observed 
was 0.00 (95% confidence limits: 0.00-0.09)1. Despite being a highly effective form of long-acting 
reversible contraception with a failure rate of less than one pregnancy per 1,000 implants inserted 
over three years2, pregnancies are regularly reported in post-marketing use.  
 
Concerns about failure to locate etonogestrel implants after insertion have highlighted the risks of 
deep insertion, migration in the arm and intravascular embolism3 4.  Impalpable implants may confer 
a risk of pregnancy if the implant has not been inserted5-7 or has been extruded/expelled8-12.  
Previous pharmacovigilance reviews, mainly of Implanon, revealed that some pregnancies were 
associated with missing implants due to non-insertion: that is failure to insert the implant and failure 
to recognise that this has happened 13-15.  
 
The single-rod etonogestrel implant Implanon was available in the UK between 1999 and 2010.    In 
2005, publications from spontaneous reporting in Australia and France, were the first to identify the 
issue of missing implants13 14. The  development of a modified radiopaque implant and applicator 
(proprietary name Nexplanon) licensed in the UK in 201016, made imaging and evaluation of these 
‘lost implants’ more straightforward.   Pregnancies in etonogestrel implant users are rare but 
continue to be reported to the UK’s Yellow Card Scheme (https://yellowcard.mhra.gov.uk/). There is 
little information reported so far on failures of Nexplanon. 
 In this study, a comparison of spontaneous reports of unintended pregnancies associated with 
Implanon and Nexplanon devices during two five-year periods was undertaken, in order to 
investigate whether problems with insertion, in particular non-insertions, have been resolved by the 
introduction of Nexplanon and its modified applicator. During this time, it is estimated that more 






Individual case reports of suspected adverse reactions are sent to regulators spontaneously by 
healthcare professionals and patients through the UK’s Yellow Card Scheme18. Clinical information 
provided in these reports is analysed by the UK Medicines and Health products Regulatory Agency 
(MHRA) and used to detect possible links between a medicine and an adverse effect19. Data derived 
from Yellow Cards and pharmaceutical companies are publicly available for each medicine in the 
form of interactive Drug Analysis Profiles (https://yellowcard.mhra.gov.uk/idap ). The inclusion of a 
reported reaction in a Drug Analysis Print does not necessarily mean it has been caused by the 
medicine, only that the reporter had a suspicion it may have been.  
 Cases of pregnancy in association with the use of Implanon and Nexplanon reported to the MHRA 
were identified for the periods 2005-2009 (Implanon) and 2012- 2016 (Nexplanon).  Since Nexplanon 
was launched towards the end of 2010 in the UK, the first quinquennium of reporting comprises 
solely Implanon devices and the second quinquennium almost entirely Nexplanon devices. 
 
 
Patient and public involvement 
 
As the study was conducted based on secondary data, contraceptive users and the public were not 
involved in the design of the study.  
 
 
Inclusion and exclusion criteria 
 
All UK spontaneous reports in the MHRA database were screened to identify reporting of pregnancy, 
from any source – e.g. healthcare professionals, patients or the pharmaceutical industry - occurring 
with etonogestrel devices. Pregnancy may have been diagnosed clinically at any time, or by the 
reporter stating that a miscarriage, ectopic pregnancy, termination of pregnancy or delivery had 
occurred. 
 
The following reports were excluded: 
• All reports from other countries 
• UK reports where the type of device was not specified 





Assessment of reports 
 
All cases were reviewed in accordance with a predefined Standard Operating Procedure developed 
prior to the start of assessment. Two assessors (EC and MH-W) were involved in retrospectively 
reviewing spontaneous reports of pregnancy associated with either device during the two reporting 
periods.  All cases were reviewed independently by at least one assessor and a subsample were 
assessed by two assessors to ensure consistency of assessment and decision-making. A third 
assessor (SR) was used for consultation on more complex cases.  Reports were assessed to 
determine whether there was sufficient information to meet the following criteria:  
1) Sufficient evidence of pregnancy (cases where patients reported symptoms, but a pregnancy test 
was negative or never confirmed were excluded) 
2) The estimated conception date was after the date of implant insertion (cases where conception 
occurred prior to implant insertion were excluded) 
   
The following additional aspects of each report were considered in order to determine the possible 
reason for failure of the implant: 
• concomitant medication: all reported medications (prescribed and non-prescribed) were 
reviewed, along with dates of administration.   
• absence of the implant: evidence that the implant was missing included information about being 
unable to palpate the implant, imaging results and/or blood etonogestrel levels being negative. 
In the absence of such information the implant was assumed to be present. 
 
For the remaining cases, reasons for failure of the method were placed into pre-determined 
categories (see Table 1) and statistical comparisons (using Chi-squared and Fisher’s Exact test) were 











Table 1       
Summary of the reasons for implant failure during post-marketing use of Implanon (2005-2009) 
and Nexplanon (2012-2016)   
 
 
Assessment Category Implanon1 Nexplanon1 Chi-squared 
Missing implant2 68 (30%) 52 (22%) P=0.08 
Drug interaction3 22 (10%) 9 (4%) P=0.02 
True method failure4 122 (53%) 148 (63%) P=0.04 
Wrong timing of insertion 17 (7%) 18 (8%) P=1.00 
Other5 0 (0%) 7 (3%)  P=0.02a 
Total 229 234  
 
a Fisher’s Exact test 
 
Notes 
1. Numbers of cases reported (percentages of total for each group).  
2. A missing implant was defined as one not in the body at the time pregnancy was diagnosed. 
3. Includes with anti-epileptic, anti-retroviral, anti-tubercular drugs and St. John’s wort 
4. This category was assigned if no other reason for pregnancy could be determined 







A total of 831 cases reporting pregnancy (377 for Implanon and 454 for Nexplanon) were retrieved 
from the database and reviewed. Of these, 463 (229 for Implanon and 234 for Nexplanon) were 






Figure 1      Cases suitable for analysis 
 
[See separate file] 
 
 
A summary of the reasons for implant failure for both devices is shown in Table 1.  True method 
failures accounted for the majority of pregnancies, with the next most common cause being missing 
implants. The frequency of each category of pregnancy cause was not significantly different when 
Implanon and Nexplanon were compared (Table 1). 
 
Missing implants 
Of 68 missing Implanon cases, only 11 contained information about palpation of the implant after 
insertion and in three of these the implant was never palpable. In addition, eight cases reported 
infection at the site of insertion; in five of these cases the implant was palpable after insertion.  
 
Of the 52 missing Nexplanon implant cases, 13 contained information about palpation of the implant 
after insertion. In five of these cases the implant could not be palpated; in seven of the eight cases in 




Of the 22 cases reported as possible drug interaction with Implanon, the drugs involved were 
carbamazepine, topiramate, rifampicin, St John’s wort and HIV medicines.  Of the nine cases of drug 
interaction associated with Nexplanon, the most commonly reported suspect drugs were HIV 
medicines, carbamazepine, rifampicin and St John’s Wort. The reports did not provide detailed 
information on the constituent drugs in the HIV medicines. 
 
 




Other device failures were applicable to Nexplanon only (n=7, 3% of Nexplanon reports). Two 
reports indicated the implant had been expelled and four cases reported a damaged or broken 




The source data for this study comprising 10 years’ experience of UK spontaneous reporting for 
etonogestrel implants and analysis of 463 reports of device failure make it the largest study of its 
kind to date.  Continuing reports of unintended pregnancy show how ‘real-life’ use of etonogestrel 
implants is not associated with the zero-failure rate seen in the clinical trials and how contraceptive 
failures still occur, despite familiarity of clinicians with the method and design changes to the 
implant/applicator in 2010. Reasons for device failure included failure to exclude pregnancy prior to 
insertion, failure to quick start correctly20, non-insertion and recognised drug interactions, which are 
all avoidable causes of pregnancy during implant use.  
 
It has been postulated that human factors may be at work in cases of non-insertion21. These types of 
medical errors could include a ‘learning curve’ effect, implying that as soon as clinicians become 
familiar with the method, errors will tend to diminish. Risk management programmes have been set 
up22 and ‘top tips’ offered to address this23 24 but our study suggests problems with implant insertion 




In the ten-year reporting period of this study there were only two reports of device expulsion and, 
even then, there was some doubt about these two cases being true extrusions because of lack of 
information in the reports.  This is consistent with the understanding that extrusions/expulsions of 
etonogestrel implants are rare causes of pregnancy and that spontaneous expulsion of a device after 
correct insertion is close to impossible25. Studies showing expulsion rates above zero have all been 
on levonorgestrel multiple-rod implants26. Factors that have been proposed as predisposing to 
expulsion with levonorgestrel implants are incomplete insertion, wound infection, instances where 
the insertion procedure is a reinsertion in the same site, physical activity or low body mass index.   
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Non-insertion appears to be a more common phenomenon than extrusion. In our study, 30% of 
Implanon cases and 22% of Nexplanon cases were due to missing implants - that is, the implant 
could not be located at the time pregnancy was confirmed. Missing implants were a significant issue 
with Implanon6; the redesign to Nexplanon was intended to address this and facilitate their 
location16. The proportion of cases associated with Nexplanon was not significantly different than 




There is accumulating evidence from published reports of pregnancies occurring after concomitant 
use of potent enzyme inducers (see Table 2). In this study, known drug-drug interactions were 
identified in 10% of Implanon cases and 4% of Nexplanon cases.  While the proportion of these 
pregnancies was numerically lower for Nexplanon, the difference between the groups was not 
significant (see Table 1). Ongoing reports with both devices suggest that awareness of drug 
interactions among prescribers needs to be repeatedly reinforced. 
 
Table 2 
Published reports of drug interactions resulting in pregnancy with the etonogestrel implant 
 
 
Enzyme inducer group Drug Spontaneous reporting Case reports 
‘Herbal’ St John’s wort Simon et al15  
Anti-tuberculous Rifampicin Simon et al15 Bacon & Mina27 
Patni28 
Gbolade29 
Anti-epileptic Phenobarbitone Bensouda-Grimaldi et al14 
Simon et al15 
 
Phenytoin Simon et al15  
Carbamazepine Harrison-Woolrych & Hill13 
Bensouda-Grimaldi et al14 




Oxcarbazepine Simon et al15  
Anti-retroviral Efavirenz Simon et al15 Matiluko32 
Lakhi33 
McCarty et al34 
Leticee et al35 








Although information regarding body mass index was missing from most reports, in 27 cases (11 
Implanon, 16 Nexplanon) the only reason identified for contraceptive failure was obesity. The 
current product information states that36:  
• plasma levels of etonogestrel are inversely related to body weight and decrease over time 
• although clinical experience is limited, the contraceptive effect in heavier women during the 
third year of use may be lower than for women of normal weight   
• earlier replacement of the implant in heavier women may need to be considered.  
 
Professional guidance points out that no increased risk of pregnancy has been demonstrated in 
women weighing up to 149kg37. This guidance also states that plasma levels high enough to block 
ovulation are not the only parameter that should be taken into consideration, as the method has 
other contraceptive mechanisms of action37. In  clinical trials, in which there was a zero failure rate, 
175 of 1,716 women (10%) weighed 70kg or more, of whom 102 continued use beyond two years1. 
Also, in the CHOICE study,  failure rates did not vary by body mass index38. 
 
Almost half of these pregnancies (13 of 27 Nexplanon reports) were reported within two years of 
insertion, but there was not enough data in the reports for a more thorough assessment. In nine of 
the obesity cases, the women were morbidly obese (BMI >45kg/m2 or weight > 110kg). Thus, 
although no other factor could be identified for these pregnancies other than obesity, some could 
also be classified as true method failures. Therefore, because of the uncertainties mentioned, cases 




In four Nexplanon cases it was reported that the implant was damaged, and this was classified as the 
reason for device failure (see ‘other’ category in Table 1). There are very limited other published 
data on this issue, although a pharmaceutical company response to an earlier case report suggested 
that breakage of an implant should not result in implant failure39. Analysis of more cases of broken 






Missing implants have previously been attributed to self-removal40 (although the number of cases is 
very small). There  have also been isolated reports of unsuccessful41 and successful42 43  self-removal 
of implants by the woman herself, after the implant had been in place for some time, not 
immediately after insertion, before the wound is fully healed.  In this study, there were no reported 
cases of implant self-removal but this may be a phenomenon that is not spontaneously reported on 






The results of this study show that the most common reason for reported failure of etonogestrel 
implants is true method failure, a diagnosis of exclusion after assessment of other possible reasons 
for unintended pregnancies. Other reasons identified for device failure in this series included missing 
devices.  A key finding was that the proportion of devices reported missing at the time of failure was 
similar for Implanon and Nexplanon.  Our assessments suggested that non-insertion of the implant 
was a reason for the missing products, which is consistent with previous studies 13. One intended 
benefit of Nexplanon was a reduction of the risk of non-insertion21 (with introduction of a ‘next-
generation applicator’) but it appears that this aim has not been achieved.   
More work, including continuing education of clinicians doing insertions, is needed on the 
prevention of avoidable causes of unintended pregnancies (e.g., failure of insertion and drug 
interactions) associated with etonogestrel implants.  
 
Strengths and limitations  
The strengths of this study are: 
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• The largest and most recent study to report post-marketing experience of etonogestrel 
contraceptive devices    
• Detailed clinical assessment of several hundred reports provides important information 
about reasons for failure of etonogestrel devices in real-world use 
• Independent study using nationwide data    
 
The limitations of the study are: 
• It is based entirely on spontaneous reporting data and could not assess overall rates of 
failure (i.e. per 100 woman-years of use) in real-life use, as utilisation data were not 
available for the full period of review                
• The amount of information for assessment was insufficient on many reports, with 
proportionally more instances for Nexplanon, and these cases had to be excluded from the 
analyses 
 
Implications for clinical practice 
History-taking must always include a detailed drug history, including non-prescription medicines. 
Timing of insertion must be confined to days 1 – 5 of the cycle, or other times as recommended in 
professional guidelines, or the woman must have been using effective contraception during the 
whole of the insertion cycle. 
Palpation of the implant in the arm by clinicians has become routine in clinical practice. 
Nevertheless, women themselves should be strongly encouraged to palpate their arm after any 
dressing is taken off and report any difficulty in identifying the presence of the implant. Women 
using contraceptive implants need to be told that they should at all times be able to feel the implant 
in their arm and that they should question the suitability of concomitant prescribed medicines. 
 
Implications for policy-makers and manufacturers 
There is potential for greater avoidance of pregnancies associated with etonogestrel implant use.  
Policy-makers need to ensure that health budgets are adequate to fund clinician updating. 
Manufacturers should strive further in the design of applicators to minimise human factors 
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